<DOC>
	<DOCNO>NCT00344487</DOCNO>
	<brief_summary>To explore hypothesis use Lopinavir/ritonavir associate improved CD4 immune reconstitution volunteer fail demonstrate significant CD4 cell increase ( first antiretroviral treatment regimen ) despite sustain viral suppression non-Lopinavir/ritonavir-containing regimen</brief_summary>
	<brief_title>Pilot Study Effect Kaletra CD4 Response HIV Positive ( + ) Patients With Viral Suppression KIMBO Study</brief_title>
	<detailed_description>This open-labeled , non-randomized exploratory trial select volunteer meet stated enrollment criterion . This study assess impact Lopinavir/ritonavir CD4 immune reconstitution . All volunteer must antiretroviral therapy sustain viral load suppression &lt; 400 copies/mL least 24 month ( , HIV-1 RNA &lt; 400 copies/mL 12 month , HIV-1 RNA &lt; 50 copies/mL 6 month prior screen ) . Despite induction viral suppression , volunteer must demonstrate limited post-antiretroviral CD4 increase . Lopinavir/ritonavir substitute one 3 ARV drug current ( baseline ) antiretroviral treatment regimen . Lopinavir/ritonavir substitute follow : 3rd NRTI , NNRTI , PI boost PI , nucleoside backbone remain . If subject currently three-drug nucleoside/nucleotide plus 4th anchor drug NRTI , NNRTI , PI boost PI regimen , triple nucleoside remain constant anchor drug substitute Lopinavir/ritonavir . Patients 2 NRTIs NNRTI PI combination allow study . Patients evaluate frequently , include physical examination , assessment development AIDS-defining condition , hematology , chemistry , lipid profile , CD4 CD8 cell count , plasma HIV-1 RNA ultrasensitive , assessment adverse event . If HIV-1 RNA become detectable , repeat confirmation 2 week . HIV genotyping phenotyping performed patient demonstrate repetitive plasma viral load level &gt; 1,000 copies/mL . An assessment memory na√Øve T cell response antiretroviral regimen change perform study . Dose dose selection Lopinavir/ritonavir also approve day dose . The dose lopinavir/ritonavir ( Kaletra ) study 400/100mg . BID 800/200mg . qd . New tablet formulation long require lopinavir/ritonavir take food . We give volunteer option day dose BID dose Kaletra . However , switch NNRTI Kaletra initially place BID dose Kaletra , allow switch once-a-day dose Kaletra 4 week study drug .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>Inclusion criterion 1 . Human Immunodeficiency Virus type1 ( HIV1 ) infection , document licensed enzymelinked immunosorbent assay ELISA ) test kit , confirm Western blot , positive HIV1 blood culture , positive HIV serum antigen , plasma viremia time prior study entry . If record exist , test must occur screen . 2 . Males nonpregnant female &gt; 18 year age . 3 . Currently stable antiretroviral regimen least 6 month prior enrollment . This stable regimen must first treatment regimen , however , prior change could make toxicity intolerability , provider use `` induction /maintenance '' type treatment strategy . 4 . HIV1 RNA &lt; 400 copies/ml ( &lt; 500 copies/ml bDNA test &lt; 40 copies/ml nucleic acid sequence base amplification [ NASBA test ] ) least 24 month ; HIV1 RNA &lt; 50 copies/ml screening ; interim , nonconsecutive viral load blip &lt; 1,000 copies/mL allow 5 . Or , HIV1 RNA &lt; 400 copies/ml ( &lt; 500 copies/ml bDNA test &lt; 40 copies/ml NASBA test ) minimum 12 month , HIV1 RNA &lt; 50 copies/ml ( &lt; 500 copies/ml bDNA test &lt; 40 copies/ml NASBA test ) 6 month prior screen , &lt; 50 copies/mL screen 6 . At minimum twelve month postinitiation antiretroviral therapy , CD4 count remain &lt; 200 cells/mm3 , baseline CD4 count 200300 , increase &lt; 50 cells/mm3 12 month period . 7 . Laboratory test within prespecified limit 8 . Able sign inform consent , willing comply requirement clinical trial . 9 . Available least 48 week follow . 10 . If female child bear potential must consent use least two form contraception 11 . Participant must Primary Care Provider order enrol study . Exclusion criteria 1 . Pregnant breastfeed woman 2 . Current treatment malignancy basal squamous cell carcinoma skin carcinoma situ cervix isolate cutaneous Kaposi 's Sarcoma treat ; prior cancer diagnosis , lymphoma must diseasefree least 5 year 3 . Absolute neutrophil count &lt; 500 , platelet count &lt; 50,000 , hemoglobin &lt; 8 gm/dL 4 . Evidence endorgan disease , define follow : renal ( calculated creatinine clearance le 50 mL/min ) ; liver ( liverassociated enzymes &gt; 3 time upper limit normal ) 5 . Grade 3 ( ACTG Grading Scale ) high cholesterol triglyceride elevation 6 . Acute , serious infection require prescription drug therapy within 30 day prior study entry 7 . In opinion investigator , evidence active ongoing opportunistic infection 8 . Must currently undergo treatment opportunistic infection . 9 . Use immune stimulation agent know impact CD4 cell count peripheral circulation , include Interleukin 2 ( IL2 ) , interferon , Granulocyte ColonyStimulating Factor ( GCSF ) , Granulocyte Macrophage Colonystimulating Factor ( GMCSF ) , etc . 10 . Use immune suppressive drug . 11 . Subject currently take follow drug : midazolam , triazolam , terfenadine , astemizole , cisapride , pimozide , propafenone , flecainide , certain ergot derivative ( ergotamine , dihydroergotamine , ergonovine , methylergonovine ) , rifampin , lovastatin , simvastatin , St. John 's Wort , doxorubicin , ribavirin , coumadin . 12 . Subject significant history cardiac , renal , neurologic , psychiatric , oncologic , endocrinologic ( include diabetes mellitus ) , metabolic , hepatic disease would , opinion investigator , adversely affect his/her participation study . 13 . Unable unwillingness discontinue use specific medication implicate drug interaction Lopinavir/ritonavir 14 . Known hypersensitivity , allergic reaction , intolerance Lopinavir/ritonavir ritonavir past 15 . Have previously receive Lopinavir/ritonavir 3 month past 16 . Active substance alcohol abuse , opinion principal investigator would interfere protocol adherence 17 . Unwillingness use effective barrier contraception . 18 . Experimental vaccine , include HIV vaccine . 19 . Patient currently enrol experimental protocol , receive experimental medication . 20 . Patients 2 nucleoside reverse transcriptase inhibitor ( NRTIs ) Nonnucleosidereverse transcriptase inhibitor ( NNRTI ) protease inhibitor ( PI ) combination allow study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>